This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

Antibody conjugates with camptothecin compounds are described, with methods of use and preparations.

The present disclosure relates, in general to methods for treating hematologic cancers comprising administering an anti-CD30 antibody drug conjugate in combination with additional cancer therapeutics such as a checkpoint inhibitor, and a chemotherapeutic regimen.

The invention provides anti-CD30 antibody-drug conjugates, such as brentuximab vedotin, and their use for the treatment of lymphoma, such as diffuse large B-cell lymphoma. The invention also provides the use of anti-CD30 antibody-drug conjugates, such as brentuximab vedotin, in combination with lenalidomide and/or anti-CD20 antibodies, such as rituximab, for the treatment of lymphoma, such as diffuse large B-cell lymphoma.

The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.

The present invention relates to immunotherapeutic approaches to treating haematological cancers. In particular the invention relates to a method for treating a haematological cancer by targeting the 5T4 antigen. As such, the invention provides a method for treating haematological cancers comprising administering to a subject a 5T4-targeting agent. The invention also provides a 5T4-specific chimeric antigen receptor (CAR) and uses thereof in treating cancers.

Anti-CD74 antibody-drug conjugates are disclosed. The anti-CD74 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD74 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD25 ADC and Gemcitabine.

The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.

The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.